Clinical Trial Update: Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of niraparib and dostarlimab (TSR-042) in recurrent/metastatic head and neck cancer is currently active but no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• JEMPERLI (DOSTARLIMAB)
• Zejula (Niraparib)

Snippet

Sponsor: Trisha Wise-Draper | Conditions: Head and Neck Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING